1 |
AHFS Drug Information, AFS 1317 (1988)
|
2 |
Scholz, H. : Pharmacological aspects of calcium channel blockers. Cardiovas. Drugs Ther. 10, 869 (1997)
DOI
ScienceOn
|
3 |
Eichelbaum, M. and Echizen, H. : Clinical pharmacology of calcium antagonists: A critical review.J. Cardiovas. Pharmacol. 6, 963 (1984)
DOI
|
4 |
Bianchetti, G., Regazzi, M., Rondanelli, R., Ascalone, V. and Morselli, P. L. : Bioavailability of diltiazem as a function of the administered dose. Biopharm. Drug Dispos. 12, 391 (1991)
DOI
ScienceOn
|
5 |
Watkins, P. B., Wrighton, S. A., Schuetz, E. G., Molowa, D. T. and Guzelian, P. S. : Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J. Clin. Invest. 80, 1029 (1987)
DOI
PUBMED
|
6 |
Lefebvre, M., Homsy, W., Caille, G. and du Souich, P. : Firstpass metabolism of diltiazem in anesthetized rabbits: Role of extrahepatic organs. Pharm. Res. 13, 124 (1996)
DOI
ScienceOn
|
7 |
Homsy, W., Caille. G. and du Souich, P. : The site of absorption in the small intestine determines diltiazem bioavailability in the rabbit. Pharm. Res. 12, 1722 (1995)
DOI
ScienceOn
|
8 |
Dixon, R. A. and Steele, C. : Flavonoids and isoflavonoids-gold mine for metabolic engineering. Trends Plant Sci. 4, 394 (1999)
DOI
ScienceOn
|
9 |
Dupuy, J., Larrieu, G., Sutra, J. F., Lespine, A. and Alvinerie, M. : Enhancement of moxidectin bioavailability in lamb by a natural flavonoid: Quercetin. Vet. Parasitol. 112, 337 (2003)
DOI
ScienceOn
|
10 |
Zhang, H., Wong, C. W., Coville, P. G. and Wanwimolruk, S. : Effect of the grapefruit flavonoid naringin on pharmacokinetics of quinine in rats. Drug Meta. Drug Interact. 17, 351 (2000)
|
11 |
Goebel, K. J. and Kolle, E. U. : High performance liquid chromatographic dertermination of diltiazem and four of its metabolites in plasma. J. Chromatogr. 345, 355 (1985)
DOI
ScienceOn
|
12 |
Hodek, P., Trefil, P. and Stiborova, M. : Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. Chem. Biol. Interact. 139, 1 (2002)
DOI
ScienceOn
|
13 |
Klaassen, C. D. Toxicology. 5th ed. New York: McGraw-Hill. 113 (1999)
|
14 |
Yusa, K. and Tsuruo, T. : Reversal mechanism of multidrug resistance by verapamil: Direct binding of verapamil to Pglycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res. 49, 5002 (1989)
|
15 |
Takanaga, H., Ohnishi, A., Matsuo, H. and Sawada, Y. : Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in caco-2 cells. Biol. Pharm. Bull. 21, 1062 (1998)
DOI
ScienceOn
|
16 |
Ford, J. M. : Modulators of multidrug resistancepreclinical studies. Hematol. Oncol. Clin. N. Am. 9, 337 (1995)
PUBMED
|
17 |
Saeki, T., Ueda, K., Tanigawara, Y., Hori, R. and Komano, T. : P-glycoprotein-mediated transcellular transport of MDR-reversing agents. FEBS Lett. 324, 99 (1993)
DOI
ScienceOn
|
18 |
Fruehauf, J. P. and Manetta, A. : Use of extreme drug resistance assay to evaluate mechanisms of resistance in ovarian cancer: Taxol resistance and MDRI expression. Contrib. Gynecol. Obstet. 19, 39 (1994)
|
19 |
Yeung, P. K., Mosher, S. J., Quilliam, M. A. and Montague, T. J. : Species comparison of pharmacokinetics and metabolism of diltiazem in humans, dogs, rabbits and rats. Drug Metab. Dispos. 18, 1055 (1990)
|
20 |
Van Asperen, J., Van Tellingen, O., Sparreboom, A., Schinkel, A. H., Borst, P., Nooijen, W. J. and Beijnen, J. H. : Enhanced oral bilavailability of diltiazem in mice treated with the p-glycoprotein blocker SDZ PSC 833. Br. J. Cancer 76, 1181 (1997)
DOI
ScienceOn
|
21 |
Kim, D. H., Jung, E. A., Sohng, I. S., Han, J. A., Kim, T. H. and Han, M. J. : Intestinal bacterial metabolism of flavonoids and its relation to some biological activities. Arch. Pharm. Res. 21, 17 (1998)
DOI
|
22 |
Bardelmeijer, H. A., Beijnen, J. H., Brouwer, K. R., Rosing, H., Nooijen, W.J., Schellens,J. H. and van Tellingen, O. : Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin. Cancer Res. 6, 4416 (2000)
|
23 |
Homsy, W., Lefebvre, M., Caille, G. and du Souich, P. : Metabolism of diltiazem in hepatic and extrahepatic tissues of rabbits: In vitro studies. Pharm. Res. 12, 609 (1995)
DOI
ScienceOn
|
24 |
Chaudhary, P. M. and Robinson, I. B. : Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66, 85 (1991)
DOI
ScienceOn
|
25 |
Rocci, M. L. and Jusko, W. J. : LAGRAN program for area and moments in pharmacokinetic analysis. Computer Programs in Biomedicine. 16, 203 (1983)
DOI
ScienceOn
|
26 |
Gottesman, M. M. and Pastan, I. : Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62, 385 (1993)
DOI
ScienceOn
|
27 |
Ito, K., Kusuhara, H. and Sugiyama, Y. : Effects of intestinal CYP 3A4 and P-glycoprotein on oral drug absorption-theoretical approach. Pharm. Res. 16, 225 (1999)
DOI
ScienceOn
|
28 |
Sterzel, P. B. : Renal actions of calcium antagonists.J. Cardiovas. Pharmacol. 10, 17 (1987)
DOI
|
29 |
Biedler, J. L. and Riehm, H. : Cellular resistance to actinomycin D in Chinese hamster cells in vitro: crossresistance, radioautographic, and cytogenetic studies. Cancer Res. 30, 1174 (1970)
|
30 |
Epstein, M. and Loutzenhister, R. D. : Effects of calcium antagonists on renal hemodynamics. Am. J. Kidney Dis. 16, 10 (1990)
|
31 |
Eagling, V. A., Profit, L. and Back, D. J. : Inhibition of the CYF 3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br. J. Clin. Pharmacol. 48, 543 (1999)
DOI
ScienceOn
|
32 |
Ho, P. C., Saville, D. J. and Wanwimolruk, S. : Inhibition of human CYF 3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J. Pharm. Pharm. Sci. 4, 217 (2001)
|
33 |
Kolars, J. C., Schmiedlin-Ren, P., Dobbins, W. O., 3rd, Schuetz, J., Wrighton, S. A. and Watkins, P. B. : Heterogeneity of cytochrome P450IIIA expression in rat gut epithelia. Gastroenterology 102, 1186 (1992)
DOI
|
34 |
The Merck Index, 12th Edition, Merck and Company., Rahway, USA. 6512 (1996)
|
35 |
Doostdar, H., Burke, M. D. and Mayer, R. T. : Bioflavonoids: Selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. Toxicology 144, 31 (2000)
DOI
ScienceOn
|
36 |
Ruilope, L. M. and Alcaar,J. M. : Renal effects of calcium entry blockers. Cardiovas. Drugs Ther. 4, 979 (1990)
DOI
|
37 |
Hermann, P. H., Rodger, S. D., Remones, G., Thenot, J. P., London, D. R. and Morselli, P. L. : Pharmacokinetics of diltiazem after intravenous and oral administration. Eur. J. Clin. Pharmacol. 24, 349 (1983)
DOI
ScienceOn
|
38 |
Nijveldt, R. J., van Nood, E., van Hoom, D. E. C., Boelens, P. G., van Norren, K. and van Leeuwen, PAM. : Flavonoids: A review of probable mechanisms of action and potential applications. Am. J. Clin. Nutr. 74, 418 (2001)
|